$200.15
7.874.09%
Last update: Nov 9, 7:59 PM
Revolution Medicines Inc
RVMDNASDAQ
Revolution Medicines rose 219.1% from $62.73 to $200.15, ahead of the S&P 500's +10.5%. Its worst day was Jan 26 (−16.9%), and its low came Nov 10 at $62.73.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Revolution Medicines shares rose 28.6%, while the S&P 500 fell 0.3%.
+28.6% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Revolution Medicines shares fell 16.9%, while the S&P 500 rose 0.5%.
−16.9%, the year's worst day · S&P 500 +0.5%
EPS of $-1.86 missed the $-1.56 estimate on $0.00 revenue (est. $11.6M).
−1.1% · S&P 500 −0.6%
Revolution Medicines shares rose 41.3%, while the S&P 500 rose 1.0%.
+41.3%, the year's best day · S&P 500 +1.0%
EPS of $-2.29 missed the $-1.84 estimate on $0.00 revenue (est. $6.1M).
−5.7% · S&P 500 −0.3%
EPS of $-3.06 missed the $-2.01 estimate on $0.00 revenue (est. $39.7M).
+0.3% · S&P 500 −0.2%
Revolution Medicines closed at its highest level of the year, 252.5% above where the year started.
+2.7% · S&P 500 +0.7%
EPS of $-1.90 beat the $-2.37 estimate on $197.6M revenue (est. $27.6M).
−11.0% · S&P 500 −4.4%
Where it ended: a close of $200.15 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-1.26, revenue est. $375.2M).
Nothing in the past 12 months.
All RVMD dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RVMD and SPY from Benzinga historical bars. Not investment advice.
